Wild gorillas carriers of a SIV virus close to the AIDS virusNovember 14, 2006
In 2005, 40.3 million people in the world, including 25.8 million in Sub-Saharan Africa, were living with HIV. The question of the origin of HIV-1, responsible for the AIDS pandemic, has been stimulating the scientific community for many years.
Some months ago, the team of Martine Peeters, director of research at IRD, and Eric Delaporte, director of the mixed research unit UMR 145 jointly involving the IRD and the University of Montpellier 1, showed the chimpanzee subspecies living in the Congo Basin (2) to be the reservoir of HIV-1 virus group M, the source of the world pandemic and that of another, very rare variant, HIV-1 group N. However, the reservoir of the third HIV-1 group, group O which infects humans (3), remained unidentified up to now.
This team announces, in an article in the journal Nature, the discovery of a simian immunodeficiency virus (SIV) infection in wild gorillas. Samples of faeces collected from different communities of gorillas found in the remotest areas of the Cameroon tropical forest were found to contain antibodies against this virus, called SIVgor. The genetic characteristics of the virus were present again in three gorillas living more than 400 km apart. Phylogenetic analysis of SIVgor showed it to be related to HIV-1 group O found in humans, essentially in Cameroon and in neighbouring countries.
This discovery of an HIV-1 related virus in wild gorillas does not, however, call into question the fact that chimpanzees are the primary reservoir of SIV/HIV viruses that crop up again in gorillas and in humans. As Martine Peeters of the IRD says, "the viruses of groups M and N are, very clearly, the consequence of inter-species transmission from chimpanzee to humans, whereas the origin of HIV-1 group O is less apparent. It cannot be excluded that chimpanzees infected by HIV-1 group O might have contaminated humans and the gorilla independently, or that the gorilla, having been contaminated by the chimpanzee, might have contaminated humans".
This work thus opens up a Pandora's box on the questions and speculations concerning the ability of these viruses to cross over from one species to another. The main challenges facing these teams for future work will be determination of the prevalence, the geographical distribution and biology of SIV infections in these great apes, not forgetting the question of how the gorillas were contaminated. This last point remains a mystery,considered as rare.
1. UMR 145: Fran Van Heuverswijn, Cecile Neel, Florian Liegeois, Christelle Butel, Eric Delaporte and Martine Peeters jointly involving the IRD and the University of Montpellier1 University of Alabama (Beatrice Hahn and her colleagues), University of Nottingham (Paul Sharp and his colleagues) PRESICA Project of Cameroon headed by Eitel Mpoudi-Ngole.
2. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Mpoudi Ngole E, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH. Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. Science. 2006 , 313 : 523-6
3. Scientists have known for a long time that the Aids virus shows a very strong genetic variability. Two main types of the virus exist: HIV 1 and HIV 2. HIV 1, the most widely spread in the world, embraces three groups (M, N,O) which manifest different genetic characteristics. Within group M, the most frequent, still 9 further subtypes can be distinguished (A, B, C, D, F, G, H, J, K), genetically close yet distinct.
Institut de Recherche Pour le Développement
Related Hiv-1 Current Events and Hiv-1 News Articles
Pursuing the destruction of HIV-infected cells
An oral drug used to treat an illness unrelated to HIV eradicated infectious HIV-producing cells in lab cultures while sparing uninfected cells - and suppressed the virus in patients during treatment and for at least eight weeks after the drug was stopped, according to results of a clinical pilot trial and researchers at Rutgers University and Dartmouth College.
HIV vaccine design should adapt as HIV virus mutates
Human immunodeficiency virus is known to be a highly variable virus that adapts to a person's immune response during the lifetime infection, and a new study published in Nature Medicine shows that viral adaptation in HIV can predict a person's current disease status, as well as the degree to which newly transmitted HIV-1 is adapted to their new host.
Findings in humans provide encouraging foundation for upcoming AIDS vaccine clinical trial
Some people infected with HIV naturally produce antibodies that effectively neutralize many strains of the rapidly mutating virus, and scientists are working to develop a vaccine capable of inducing such "broadly neutralizing" antibodies that can prevent HIV infection.
Osel scientists engineer vaginal lactobacillus to express neutralizing HIV-1 antibody fragments
A normal, predominant bacterial species of the healthy vaginal microbiota can be engineered for potential use as a novel protective agent against HIV-1 transmission in women, according to a new publication from scientists at Osel, Inc. and their collaborators.
Temple scientists eliminate HIV-1 from genome of human T-Cells
A specialized gene editing system designed by scientists at the Lewis Katz School of Medicine at Temple University is paving the way to an eventual cure for patients infected with HIV, the virus that causes AIDS.
New research could help improve HIV/AIDS therapies
Hideki Aihara, Zhiqi Yin, and Ke Shi of the University of Minnesota, along with colleagues from Cornell University and St. Louis University have made a major stride in exploring new therapies to combat HIV/AIDS and retrovirus-based cancers.
Progress toward an HIV cure highlighted in special issue of AIDS Research and Human Retroviruses
A cure for HIV/AIDS is the ultimate goal of rapidly advancing research involving diverse and innovative approaches.
Effects on HIV and Ebola
Scientists at the Helmholtz Zentrum München discover that extracts of the medicinal plant Cistus incanus (Ci) prevent human immunodeficiency viruses from infecting cells.
Adenosine deaminase may help the immune system fight HIV on its own
New research findings published in the February 2016 issue of the Journal of Leukocyte Biology, suggest that a new therapeutic strategy for HIV may already be available by repurposing an existing prescription drug.
Neural networks adapt to the presence of a toxic HIV protein
Nearly half of HIV infected patients suffer from impaired neurocognitive function. The HIV protein transactivator of transcription (Tat) is an important contributor to HIV neuropathogenesis because it is a potent neurotoxin that continues to be produced despite treatment with antiretroviral therapy.
More Hiv-1 Current Events and Hiv-1 News Articles